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Abstract An automated in-capillary assay requiring very
small quantities of reagents was developed for performing
in vitro cytochrome P450 (CYP450) drug metabolism
studies. The approach is based on the following: (i)
hydrodynamic introduction of nanoliter volumes of sub-
strate and enzyme solutions in the sandwich mode, within a
capillary; (ii) mixing the reagents by diffusion across the
interfaces between the injected solutions; (iii) collection of
the capillary content at the end of the in-capillary assay; and
(iv) off-line analysis of the incubation mixture by ultrahigh
pressure liquid chromatography–tandem mass spectrometry
(UHPLC-MS/MS). After optimizing the injection sequence
of the reagents, the in-capillary approach was applied to the
quantitative determination of the kinetics of drug metabo-
lism reactions catalyzed by three CYP450 isozymes
involved in human drug metabolism: CYP1A2, CYP2D6,
and CYP3A4. It was demonstrated that this in-capillary
method was able to provide similar kinetic parameters for
CYP450 activity (e.g., Michaelis constants and turnover
values) as the classical in vitro method, with a drastic
reduction of reagent consumption.
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Introduction
Cytochrome P450 (CYP450) enzymes consist of a super-
family of heme-containing proteins that generally catalyze
the transfer of a single oxygen atom onto a xenobiotic or an
endogenous substrate (e.g., steroids, fatty acids, and
prostaglandins) with NADPH as the cofactor [1–3]. This
monooxygenation reaction involves several steps and
results in diverse chemical modifications of the substrates,
such as C-atom hydroxylation, heteroatom oxygenation, and
dealkylation [4, 5]. The CYP450-catalyzed modifications
generally increase the polarity of xenobiotics, producing
metabolites that are more amenable to excretion.
Hence, these enzymes are involved in human drug
metabolism, accounting for as much as 75% of the
biotransformation of marketed pharmaceuticals [2, 6]. In
humans, CYP450-dependent drug metabolism is mainly
mediated by five hepatic isozymes, namely CYP1A2,
CYP2C9, CYP2C19, CYP2D6, and CYP3A4 [2]. The
genetic polymorphism of some of these isoforms, e.g.,
CYP2D6, CYP2C9, and CYP2C19, together with other
factors, such as age, gender, and nutritional habits, is at the
origin of the observed strong variability in CYP450-
mediated drug clearance [7]. Alteration of this enzymatic
activity can also be the consequence of CYP450-based
drug–drug interactions (DDI) [7, 8]. In this case, the
metabolic rate of a drug is modified by the coadministration
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of a second drug acting as a CYP450 isozyme(s) inhibitor
or inducer. In addition, CYP450-catalyzed reactions can
lead to the formation of pharmacologically active or toxic
drug metabolites (e.g., the biotransformation of acetamin-
ophen into N-acetyl-p-benzoquinone imine) [9].
As a result, knowledge about CYP450-mediated drug
metabolism is of primary importance to the pharmaceutical
industry, and the characterization of interactions between
these enzymes and potential drug candidates is now a
routine task in early drug discovery [10, 11]. The purpose
of these studies is to rapidly identify compounds with
unfavorable metabolic properties, such as a high suscepti-
bility to biotransformation (i.e., a low metabolic stability)
or with a high risk for CYP450-based DDI [10–12],
reducing the risk of highly costly late-stage failures. For
cost and time reasons, these early studies are generally
carried out in vitro by incubating compounds of interest
with human liver microsomes or recombinant expressed
human CYP450 (rCYP450) isozymes [10, 13]. Although
suitable for automation and for high-throughput studies
using robotic systems, these enzymatic assays are commonly
performed in relatively large incubation volumes (100 μL or
more) requiring large quantities of costly enzymes and
candidate drugs. This is particularly disadvantageous if
metabolic properties of numerous compounds have to be
determined, as in the drug discovery phase.
Recently, a novel approach for performing qualitative in
vitro CYP450-based drug metabolism and DDI studies in a
fused silica capillary was presented [14]. As the volume of
such a capillary was in the microliter range, only nanoliter
volumes of reagents were required, allowing a drastic
reduction of enzyme and compound consumption per assay
compared to the classical approach (up to a factor of
100–500). The various solutions required for an enzymatic
assay were introduced into the capillary as distinct plugs
by hydrodynamic injection, i.e., by applying a positive
pressure at the capillary inlet for a defined period of time.
Thereafter, the enzymatic reaction took place within the
capillary, the reagents encountering each other by diffusion
across the parabolic interfaces between the plugs that result
from their hydrodynamic injection. This type of mixing
within a capillary is known as transverse diffusion of
laminar flow profiles (TDLFP) [15, 16]. Because diffusion
is a fundamental property of all molecules [17], in-capillary
assays with six major CYP450 isozymes and substrates were
subsequently achieved by using the same generic procedure.
Furthermore, in contrast to the electrophoretically mediated
microanalysis technique [18–20] and other similar approaches
used to perform enzymatic assays and analyte separation in a
single capillary [21, 22], this method was based on an off-line
analysis of the incubation mixture. The decoupling of the
in-capillary CYP450 assay from the analysis offered several
advantages, such as the possibility of directly transferring the
experimental conditions from the classical in vitro assay (e.g.,
type, ionic strength, and pH of the incubation buffer) to the
in-capillary approach, and rapidly analyzing the capillary
content by ultrahigh pressure liquid chromatography–mass
spectrometry (UHPLC-MS), a very suitable analytical
technique for drug metabolism studies [23–25].
In this work, the development of the in-capillary approach
focused on the quantitative determination of CYP450
kinetics of four well-known drug metabolism reactions,
the CYP2D6-dependent O-demethylation of dextromethor-
phan [26, 27] and tramadol [28], the CYP1A2-dependent
deethylation of phenacetin [29], and the CYP3A4-dependent
1′-hydroxylation of midazolam [29, 30]. The results of the
in-capillary CYP450 activity studies, e.g., Michaelis con-
stants and turnover values, were compared to those obtained
with the conventional in vitro method.
Experimental
Chemicals and reagents
Human CYP450 Baculosomes Reagents were purchased
from Invitrogen (Basel, Switzerland). β-Nicotinamide
adenine dinucleotide 2′-phosphate reduced tetrasodium salt
(NADPH), 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic
acid (HEPES), dextromethorphan hydrobromide, dextrorphan
tartrate, phenacetin, acetaminophen, and ammonium hydrox-
ide were obtained from Sigma-Aldrich (St-Louis, MO,
USA). Tramadol and O-desmethyltramadol, as hydro-
chloride salts, were a gift from Grünenthal (Stolberg,
Germany). Midazolam was kindly donated by Dr. Y. Daali
from the Division of Clinical Pharmacology and Toxicology
at the Geneva University Hospitals. 1′-Hydroxymidazolam
was purchased from Cerilliant (Round Rock, TX, USA).
Methanol (MeOH), acetonitrile (ACN), and formic acid
(99%) of UHPLC-MS grade were purchased from Biosolve
(Valkenswaard, the Netherlands). Water was obtained
from a Milli-Q Water Purification System (Millipore,
Bedford, MA, USA).
Baculosomes stock solutions were stored at −80 °C.
After initial thawing, small aliquots were prepared and
refrozen to limit freezing/thawing cycles. Small aliquots of
NADPH stock solutions at 50 mM were also prepared in
water and stored at −80 °C. To reach suitable concen-
trations for in-solution and in-capillary CYP450-based
experiments, analyte stock solutions at 1 mg/mL in MeOH
were appropriately diluted with 50 mM HEPES buffer
solution. The latter (incubation buffer) was prepared by
dissolving the appropriate amount of HEPES in water and
adjusting pH to 7.4 with 1 M KOH in water. Ammonium
formate buffer 10 mM was prepared by mixing the required
volume of ammonium hydroxide with water and adjusting
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the pH to 9.0 with formic acid. The pH of both buffer
solutions was measured with a Metrohm pH meter
(Herisau, Switzerland).
Classical in-solution CYP450 assays
Metabolite formation time course experiments
The classical in-solution CYP2D6-dependent dextrome-
thorphan O-demethylation time course experiment (i.e.,
dextrorphan production as function of time) was performed
in a final incubation volume of 150 μL. The rCYP2D6
stock solution (1.1 pmol/μL) was diluted eight times with
the incubation buffer, i.e., 50 mM HEPES pH 7.4. Of this
diluted enzyme solution, 7.5 μL was taken and mixed with
61.5 μL incubation buffer and 75 μL of 100 μM dextro-
methorphan solution to reach the final substrate concentra-
tion of 50 μM (final CYP2D6 enzyme concentration
6.9 fmol/μL). After a pre-incubation of 5 min at room
temperature, the enzymatic reaction was initiated by adding
6 μL NADPH 50 mM (final concentration 2.0 mM) and
continued at 37 °C. Aliquots of 30 μL were removed after
5, 10, 20, and 30 min and mixed with the same volume of
ice-cold ACN to stop the reaction. After centrifugation
(5 min at 10,000 rpm), 10 μL of each supernatant was taken
and mixed with 140 μL of a water/ACN mixture (60:40 v/v)
for injection (2 μL) into the UHPLC-MS/MS system.
This procedure was then applied to dextromethorphan
0.5 μM and to other metabolite formation time course
experiments, namely for CYP2D6-dependent O-demethylation
of tramadol, CYP1A2-dependent deethylation of phenacetin
(final CYP1A2 concentration 6.25 fmol/μL), and CYP3A4-
dependent 1′-hydroxylation of midazolam (final CYP3A4
concentration 5.9 fmol/μL) at substrate concentrations of 5,
10, and 0.5 μM, respectively. These additional assays were
performed to determine the linear range of the four enzymatic
reactions at the lowest substrate concentration employed in
the classical and in-capillary enzyme kinetics studies and to
choose the incubation time.
CYP450 enzyme kinetics studies
The same protocol was employed for the biotransforma-
tions of dextromethorphan to dextrorphan and tramadol to
O-desmethyltramadol catalyzed by CYP2D6, as well as
for the conversion of phenacetin to acetaminophen and
midazolam to 1′-hydroxymidazolam catalyzed by CYP1A2
and CYP3A4, respectively. The experiments were per-
formed in a final volume of 100 μL at increasing substrate
concentrations: 0.25, 0.5, 1, 2, 5, 10, 25, 50 μM dextro-
methorphan; 5, 10, 25, 50, 100, 200 μM tramadol; 10, 20,
40, 60, 100, 150, 250 μM phenacetin; and 0.5, 1, 2.5, 5, 10,
25, 50, 100 μM midazolam. The corresponding rCYP450
isozyme stock solutions (CYP2D6, CYP1A2, and
CYP3A4) were diluted eight times with the incubation
buffer. Of these diluted enzyme solutions, 5 μL was mixed
with 41 μL incubation buffer and 50 μL of substrate
solution at twice the concentration needed for the assay.
After a pre-incubation of 5 min at room temperature, the
enzymatic reactions were initiated by adding 4 μL NADPH
50 mM (final concentration 2.0 mM) at 37 °C. Based on
corresponding time course experiments (see above), the
following incubation times were chosen: 5 min for
CYP2D6/dextromethorphan and CYP3A4/midazolam, and
10 min for CYP2D6/tramadol and CYP1A2/phenacetin.
The enzymatic reactions were then stopped by adding
100 μL of ice-cold ACN to the incubation mixtures. After
centrifugation (5 min at 10,000 rpm), 10 μL of each
supernatant was taken and mixed with 140 μL of a water/
ACN mixture (60:40 v/v) for injection (2 μL) into the
UHPLC-MS/MS system.
In-capillary CYP450 assays
All experiments were performed in a fused-silica capillary
of 1.4-μL volume (75-μm I.D., 32.5-cm length) coated with
polyvinyl alcohol to reduce adsorption on the capillary wall
[31, 32]. CYP2D6, CYP1A2, and CYP3A4 Baculosomes
stock solutions were diluted six times with incubation
buffer to obtain a final protein concentration of about
0.17 pmol/μL. NADPH was contained in the substrate(s)
solution employed in the various assays at a concentration
of about 2.0 mM. An HP3D capillary electrophoresis (CE)
system (Agilent, Waldbronn, Germany) was employed
to automate liquid handling and to thermoregulate the
capillary at 37 °C. The first step consisted of rinsing the
capillary with the incubation buffer by applying a pressure
of 1 bar for 0.5 min. Thereafter, the required CYP450
enzyme and substrate solutions were injected into the
capillary in a substrate-enzyme-substrate sequence, apply-
ing a positive pressure of 50 mbar. To introduce substrate
plugs of approximately 8% or 44% of the capillary length,
this pressure was applied for 6 s (Fig. 1a) or 33 s (Fig. 1b),
respectively, whereas 3 s was used to inject the enzyme
plug (approximately 4% of the capillary length). In the case
of substrate plugs of 8% capillary length (Fig. 1a),
incubation buffer solution was injected (50 mbar for 30 s)
to place the previously injected enzyme and substrates
plugs in the central part of the capillary and ensure
temperature control during the incubation by the CE
instrument’s air-streaming system. The incubation time
was chosen according to the experiment of interest (see
below), and during this step, empty vials were placed at
both extremities of the capillary. At the end of the chosen
reaction time, the capillary was flushed with water (1 bar
for 0.5 min) that, together with the reaction mixture, was
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led into a vial containing 30 μL of a water/ACN mixture
(1:1 v/v) to stop the enzymatic reaction. The solution
contained in this vial, 40 μL in total, was directly injected
(2 μL) into the UHPLC-MS/MS system for substrate and
metabolite analysis.
This procedure was applied to perform the same
assays as with the classical in-solution approach described
above. For the CYP2D6-dependent dextromethorphan
O-desmethylation time course experiment, in-capillary
assays were performed for an incubation time of 5, 10,
20, and 30 min at a dextromethorphan concentration
of 50 μM. For enzyme kinetics studies of CYP2D6-
dependent O-desmethylation of dextromethorphan and
tramadol, CYP1A2-dependent deethylation of phenacetin,
and CYP3A4-dependent 1′-hydroxylation of midazolam,
the same substrate concentrations and incubation times
were used as with the conventional approach.
Since the in-capillary assays were performed in a
consecutive manner with a CE instrument, the CYP450
assays were singularly carried out for each substrate
concentration on the same day. As a consequence, the
kinetic parameter’s uncertainty was estimated from the
regression error with the most appropriate enzyme kinetic
model.
UHPLC-MS/MS analysis
Off-line analysis was achieved with an ACQUITY UPLC
hyphenated to a triple quadrupole (TQD) MS/MS system
(Waters, Milford, MA, USA) operated in the selected
reaction monitoring (SRM) mode. The UPLC can withstand
up to 1,000 bar and includes a binary solvent manager, a
sample manager equipped with an injection loop volume of
2 μL (full loop injection), and a column oven set at 40 °C.
Data acquisition, data handling, and instrument control
were performed by the Masslynx v 4.1. software (Waters,
Milford, MA, USA). Analytes were separated in gradient
mode (A: 10 mM ammonium formate pH 9.0; B: MeOH, 5
to 95% B in 1 min, hold at 95% B to 1.3 min, then column
reconditioning at 5% B to 2 min) at 0.5 mL/min and the
first 0.5 min was diverted to the waste. The column was
a Waters ACQUITY UPLC BEH RP18 (50 mm×2.1-mm
I.D., 1.7 μm). Extra-column volume of the UPLC-MS/MS
configuration was experimentally estimated at about 22 μL
and dwell volume at 100μLwith the 2-μL injection loop [33].
For optimizing MS conditions and MS/MS analyte
transitions, standard solutions of each compound at 1 μg/mL
in ACN/water 1:1 (v/v) were infused into the MS system at a
flow rate of 10 μL/min. Optimal parameters and MS/MS
transitions are summarized in Table 1. MS/MS experiments
were performed in positive ion mode under constant
electrospray conditions. The capillary and the source
extractor voltages were set at 3.5 kV and 2 V, respectively.
The source temperature was maintained at 140 °C, the
desolvation gas temperature and flow rate at 450 °C and
800 L/h, respectively, and the cone gas flow rate at 50 L/h.
Analytes were monitored with a 50-ms dwell time for each
MS/MS transition. Initial experiments were performed for
evaluation of the response function in the range of 10 to
250 nM. Because the MS response followed a linear
relationship without any significant intercept, an external
calibration with one concentration level at 35 nM was
selected. Another solution at the same concentration was
employed as quality control and was regularly injected along
with the analysis sequences of incubation mixtures to check
the response of the detector.
Prism v. 4.0 (GraphPad Software, San Diego, CA, USA)
was employed to determine the most appropriate enzyme
kinetics model and the corresponding kinetic parameters
(e.g., Michaelis constants and turnover values) for the four
CYP450-catalyzed probe substrate biotransformations. The
turnover, expressed in picomole of product per minute per
picomole of CYP450, was calculated from the produced
metabolite quantities (produced in-capillary or with the
H3C
O
H3C
O
H3C
O
N    CH3
N    CH3
N    CH3
«8-4-8»
«44-4-44»
H3C
O
N    CH3
injection collection
injection collection
a
b
Fig. 1 a 8-4-8 and b 44-4-44 injection setups used for in-capillary
CYP450 assays. Configurations refer to percentage of capillary length
of substrate and enzyme plugs injected in the sandwich mode into the
capillary. For detailed assays conditions, see text
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classical approach), the employed enzyme quantities, and
the incubation times. The presented 95% confidence
intervals of the kinetic parameters result from the determi-
nation of the regression error between experimental data
and the most appropriate enzyme kinetics model.
Results and discussion
Qualitative studies with six CYP450 isozymes as well as
CYP2D6 inhibition experiments were performed as a proof-
of-concept of the in-capillary method and described
elsewhere [14]. In all in-capillary assays, substrates and
CYP450 enzyme solutions were injected within the
capillary as short plugs of equal length in the sandwich
mode, without any further optimization of the method. The
efficacy of this injection mode compared to the injection
of a single substrate and an enzyme plug has already
been demonstrated in the literature for other in-capillary
enzymatic assays [17].
In this paper, the performance of the in-capillary method
in providing quantitative results on CYP450 activity was
determined. For this purpose, some modifications of the
injection sequence were evaluated for the kinetics of well-
known drug metabolism reactions catalyzed by three
CYP450 isozymes (CYP1A2, CYP2D6, and CYP3A4).
Optimization of operating parameters can include the
following: (i) length of the injected plugs, (ii) applied
pressure, and (iii) initial concentration of the injected
enzyme solution, i.e., dilution of the enzyme stock solution.
Initial experiments were performed by diluting the
enzyme stock solution six times with incubation buffer to
decrease its viscosity and increasing diffusion of substrate
molecules into the enzyme-containing zone.
Although the enzyme concentration was not uniform
along the capillary [15, 16], this dilution was chosen to
obtain average in-capillary enzyme concentrations similar
to those used for classical in-solution assays performed
within an incubation volume of 100 or 150 μL (see Sect.
“Classical in-solution CYP450 assays”). The injection
pressure was maintained at 50 mbar, the maximum
programmable value on the commercial CE instrument,
allowing the introduction of small enzyme plugs of 8 or 4%
of the capillary length.
Thus, only the length of the substrate and enzyme plugs
was varied, and its effect was evaluated on the kinetics of
CYP2D6-catalyzed biotransformation of dextromethorphan
into dextrorphan. Firstly, preliminary experiments at low
dextromethorphan concentration (i.e., 1 μM) were carried
out to evaluate the appropriate CYP450 amount for
quantitative in-capillary assays by varying the length of
the enzyme plug from 2 to 8% of the capillary length.
Assays performed with the 8% enzyme plug did not double
the initial rate of product formation as in the case of 2% and
4% enzyme plugs (data not shown), but resulted in a lower
activity than expected, suggesting that mixing with the
substrate was partially achieved with this configuration.
Further experiments evaluating the modification of the
substrate plug length were thus performed with the enzyme
plug kept at 4% of the capillary length.
Effect of injection setup on in-capillary enzymatic activity
Time course experiments performed at saturating enzyme
conditions represent a suitable strategy for determining
CYP450 turnover values for a given substrate. This can be
achieved independently of chosen incubation times by
determining slopes of the linear relationship between
incubation times and obtained metabolite amounts. Thus,
to study the effect of the length of the injected substrate
plugs on enzymatic activity within the capillary, CYP2D6-
catalyzed biotransformation of dextromethorphan into
dextrorphan was determined as a function of time. All
these time course experiments were performed at a dextro-
methorphan concentration of 50 μM and results were
compared to those obtained in-solution.
The starting point for in-capillary assays was an injection
sequence, henceforth referred to as 8-4-8 method (Fig. 1a),
which consisted of the introduction of substrate plugs of
8% of the capillary length around the enzyme plug of 4% in
Table 1 MS and MS/MS parameters used for the analysis of the CYP450-mediated selected biotransformations
CYP450 Compounds SRM transition (m/z) Cone voltage (V) Collision energy (eV)
CYP1A2 Phenacetin 180Y110 25 15
Acetaminophen 152Y110 30 13
CYP2D6 Dextromethorphan 272Y171 50 39
Dextrorphan 258Y157 50 37
CYP2D6 Tramadol 264Y58 30 17
O-Desmethyltramadol (M1) 250Y58 25 15
CYP3A4 Midazolam 326Y291 46 28
1′-Hydroxymidazolam 342Y324 40 19
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the sandwich mode followed by a long plug of incubation
buffer solution (approximately 40% of the capillary length).
Injection of the latter was required to position the injected
enzyme and substrate plugs in the central part of the
capillary that was correctly thermoregulated at 37 °C by the
air-streaming of the CE instrument. Application of this
configuration to the O-demethylation of dextromethorphan
by CYP2D6 resulted in a dextrorphan formation time
course significantly different from the reference one
(Fig. 2). Taking into account incubation time points from
5 to 20 min, in-capillary turnover with the 8-4-8 setup
(3.9 pmol/min/pmol) was only 50% of the corresponding
reference value (7.9 pmol/min/pmol). Thus, although the
substrate injected into the capillary had the same concen-
tration as in classical in-solution assay, the kinetics obtained
with the 8-4-8 in-capillary setup was representative of a far
more diluted substrate solution. As a matter of fact,
injection of incubation buffer after introduction of reagents
plugs improved their mixing within the capillary but also
diluted them [17]. In contrast, when the capillary was
almost completely filled with the substrate solution around
the central enzyme zone, a significant improvement of the
kinetics of dextrorphan formation was observed. In fact, by
injecting substrate plugs of 44% of the capillary length
(henceforth referred to as the 44-4-44 setup, see Fig. 1b),
the initial rate of the in-capillary CYP2D6-catalyzed
biotransformation of dextromethorphan matched the refer-
ence value. Good correspondence in terms of turnover
values was therefore obtained between in-capillary
(8.0 pmol/min/pmol) assays with the 44-4-44 setup and
the classical in-solution approach (7.9 pmol/min/pmol).
Thus, although this injection setup consumed approximately
5.5 times more substrate solution than the 8-4-8 setup,
the in-capillary CYP450 kinetics studies presented below
were performed with the 44-4-44 configuration.
In-capillary and in-solution CYP450 kinetics studies
Preliminary biotransformation time course experiments
were initially performed with the classical in-solution
approach to determine the suitable incubation time for
the four selected probe substrate biotransformations, O-
demethylations of dextromethorphan to dextrorphan and
tramadol to O-demetyltramadol catalyzed by CYP2D6,
deethylation of phenacetin to acetaminophen catalyzed
by CYP1A2, and hydroxylation of midazolam to 1′-
hydroxymidazolam catalyzed by CYP3A4 (Table 1).
These assays were carried out at the lowest probe substrate
concentration used for subsequent kinetics studies. The
chosen incubation times (5 min for dextromethorphan
and midazolam and 10 min for phenacetin and tramadol)
were within the determined linear ranges of preliminary
metabolite formation time course experiments.
The in-capillary approach with the 44-4-44 injection
setup was then applied to determine kinetics of four
selected biotransformations. To this end, the initial metab-
olite formation rates were assessed at increasing substrate
concentrations and the results compared to those obtained
with classical experiments. The conditions used for the
latter, in particular probe substrate concentrations and
incubation times, were directly transferred to the in-
capillary approach. As already described, analysis of
substrates and metabolites obtained from both approaches
was performed off-line by UHPLC-MS/MS. Figure 3 shows
typical chromatograms obtained for the four studied
CYP450 biotransformations using the in-capillary method.
The most appropriate enzyme kinetics model and the
corresponding kinetic parameters (e.g., Michaelis constants
and turnover values) for the four CYP450/substrate pairs
were determined from the amounts of metabolites pro-
duced. As reported in Fig. 4, the four CYP450 kinetics
determined by the 44-4-44 in-capillary procedure showed a
similar profile as those obtained in-solution. All studied
biotransformations followed Michaelis–Menten kinetics
except hydroxylation of midazolam catalyzed by CYP3A4.
For the latter, a substrate inhibition kinetics was found in
agreement with the literature [34, 35], resulting in a
decrease of midazolam hydroxylation rates at high substrate
concentrations. In all four cases, Michaelis constants and
turnover values determined with the in-capillary approach
by simply transferring experimental conditions from clas-
sical assays were very close to those of the classical
method. No significant difference was observed in terms of
Michaelis constants if taking into account 95% confidence
intervals resulting from the determination of the regression
error between experimental data and the most appropriate
enzyme kinetics model. A good agreement was also found
for turnover values between the two approaches, particularly
for dextromethorphan/CYP2D6 and midazolam/CYP3A4
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Fig. 2 Dextrorphan formation time course experiments performed
with classical in-solution approach (continuous black line), 8-4-
8 (grey line), 44-4-44 (black dotted line) in-capillary setups. Assays
were carried out at a dextromethorphan concentration of 50 μM,
corresponding to CYP2D6 saturating conditions
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biotransformations (see Table 2). Concerning estimation of
the latter parameter, it should be noted that estimation of
maximum velocities with the in-capillary method strongly
depends on accurate determination of the incubation time
(enzymatic reaction started before the complete injection of
the reactants sequence, i.e., with the injection of the enzyme
plug). This is particularly important when performing studies
using single time points for the incubations at a given
substrate concentration (e.g., Michaelis–Menten kinetics
studies). Thus, for more accurate determination of turnover
values, time course experiments (i.e., metabolite production
as a function of time) at saturating concentrations of
substrate have to be preferentially selected (see Sect. “Effect
of injection setup on in-capillary enzymatic activity”).
Finally, the in-capillary determination of Michaelis
constants was rapid, generic, and cost-effective, and this
method could be applied to a huge number of compounds,
e.g., in the drug discovery process.
Conclusion
An attractive method for performing in-capillary CYP450
activity assays was presented. Nanoliter volumes of enzyme
and substrate solutions were injected into the capillary as
distinct plugs by hydrodynamic injection. This method is
generic because, after introducing reagents in the sandwich
mode, mixing within the capillary is achieved by TDLFP.
This approach was evaluated by providing in vitro
quantitative CYP450 enzyme kinetics data for four probe
substrate biotransformations, namely CYP2D6-catalyzed
O-demethylations of dextromethorphan to dextrorphan
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Fig. 3 Examples of SRM chromatograms corresponding to
selected CYP450-mediated biotransformations: a dextromethorphan
O-desmethylation by CYP2D6; b tramadol O-desmethylation by
CYP2D6, c phenacetin O-deethylation by CYP1A2, and d midazolam
1′-hydroxylation by CYP3A4. Chromatograms correspond to in-
capillary incubations with the 44-4-44 injection setup at substrate
concentrations close to the obtained Michaelis constant values, i.e.,
1 μM for dextromethorphan, 25 μM for tramadol, 40 μM for
phenacetin, and 2.5 μM for midazolam. The peak highlighted with
an asterisk resulted from an in-source MS fragmentation of phenacetin
in conditions used for the analysis
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and tramadol to O-desmethyltramadol, CYP1A2-catalyzed
deethylation of phenacetin to acetaminophen, and
CYP3A4-catalyzed hydroxylation of midazolam to 1′-
hydroxymidazolam. The substrate plug length had a strong
influence on metabolite production for dextromethorphan
O-demethylation. The results obtained by using the 8-4-
8 injection setup were not in agreement with those obtained
classically because substrate dilution occurred within the
capillary. This was shown to significantly decrease the rate
of dextromethorphan O-demethylation compared to the
classical in-solution experiment. Substrate plugs were then
increased to 44% of the capillary length (44-4-44 injection
setup), avoiding in-capillary substrate dilution, and almost
identical CYP450 kinetic profiles as with the classical in-
solution approach were obtained for the four selected
CYP450/substrate pairs. With single incubation time points
at a given substrate concentration, it was thus possible to
determine kinetic parameters (e.g., Michaelis constants and
turnover values) with the in-capillary method, which were
very close to the reference values. This was particularly true
for relative kinetic parameters, such as the Michaelis constant.
Determination of absolute parameters, e.g., the turnover, is
also possible, as shown for the initial rate of dextrorphan
production catalyzed by CYP2D6. In this case, assays have to
be preferentially performed at different incubation time points.
Finally, to increase productivity of CYP450 assays, a
multi-capillary system is under construction to perform
twelve experiments in parallel.
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Fig. 4 Enzyme kinetics plots
for selected CYP450-mediated
biotransformations obtained
with the 44-4-44 in-capillary
setup (dotted line) and the
classical approach (continuous
line): a dextromethorphan
O-desmethylation by CYP2D6;
b tramadol O-demethylation
by CYP2D6, c phenacetin O-
deethylation by CYP1A2, and d
midazolam 1′-hydroxylation by
CYP3A4. A Michaelis–Menten
kinetics resulted for all
biotransformations, except for
the conversion of midazolam
into 1′-hydroxymidazolam
catalyzed by CY3A4 (substrate
inhibition kinetics)
Table 2 Enzyme kinetic models and corresponding kinetic parameters for the four selected CYP450-mediated biotransformations obtained with
the 44-4-44 in-capillary setup and the classical approach
CYP450 Substrate Kinetic model KM (μM) Turnover (pmol/min/pmol) Ki (μM) r
2
CYP1A2 Phenacetin Michaelis–Menten In-solution 51.0±5.0 39.0±1.3 – 1
In-capillary 47.0±5.5 35.2±1.4 1
CYP2D6 Dextromethorphan Michaelis–Menten In-solution 0.6±0.2 8.1±0.4 – 0.99
In-capillary 0.7±0.1 8.3±0.4 0.99
CYP2D6 Tramadol Michaelis–Menten In-solution 26.2±10.1 19.9±2.4 – 0.99
In-capillary 26.0±3.7 30.0±1.3 1
CYP3A4 Midazolam Substrate inhibitiona In-solution 2.9±1.5 13.8±3.3 53.8±31.2 0.9820
In-capillary 3.2±1.3 12.5±2.3 87.1±45.4 0.99
a Equation 6 from [35]
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